NR3C2 and chronic kidney disease: Chupradit et al. reported that finerenone, a non-steroidal mineralocorticoid receptor antagonist, shows moderate cardiovascular benefit, particularly in reducing heart failure outcomes in patients with chronic kidney disease and type 2 diabetes [27].